| Phase 11 trial |
|
Phase 1
|
NCT00000974 |
? → Sep 1996 |
HIV infectious disease, pneumocystosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT03403621 |
Mar 2018 → Feb 2020 |
reactive cutaneous fibrous lesion |
Mayo Clinic |
Terminated
|
No outcome recorded
Stop: Business |
| Phase 23 trials |
|
Phase 2
|
NCT01844791 |
Sep 2012 → Jan 2014 |
non-small cell lung carcinoma |
Oncozyme Pharma Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01378143 |
Mar 2011 → Mar 2014 |
colorectal cancer |
Oncozyme Pharma Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00001996 |
— |
HIV infectious disease, pneumocystosis |
Glaxo Wellcome |
Completed
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT00000991 |
? → Apr 1994 |
HIV infectious disease, pneumocystosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT00002340 |
— |
HIV infectious disease, pneumocystosis |
Glaxo Wellcome |
Completed
|
No outcome recorded
|
| Phase not applicable1 trial |
| — |
NCT00002053 |
— |
HIV infectious disease, pneumocystosis |
Fisons |
Completed
|
No outcome recorded
|
| Comparator or background therapy1 trial |
|
Phase 3
|
NCT07463040 Comparator |
Jan 2027 → Mar 2029 expected |
cutaneous leishmaniasis |
Institute of Tropical Medicine, Belgium |
Not yet recruiting
|
No outcome recorded
|